Copyright
©The Author(s) 2022.
World J Psychiatry. May 19, 2022; 12(5): 739-765
Published online May 19, 2022. doi: 10.5498/wjp.v12.i5.739
Published online May 19, 2022. doi: 10.5498/wjp.v12.i5.739
Table 1 21 studies that are included in meta-analysis for Middle East respiratory syndrome
Study ID | Ref. | Study type | Sample size | Country | Exposure | Outcome | P value | Quality assessment (NOS) |
1 | Shin et al[36] | Quantitative | 63 | Korea | MERS patients | PTSD, Sleep problem, anxiety, depression, suicidality, phobic anxiety, addiction, aggression | Not specified | 7 |
2 | Um et al[37] | Quantitative | 64 | Korea | MERS patients and HCWs | PTSD, depression | Not specified | 7 |
3 | Abolfotouh et al[38] | Quantitative | 1031 | Saudi Arabia | HCWs | Level of Concern | Not specified | 7 |
4 | Jung et al[39] | Quantitative | 147 | Korea | HCWs | PTSD | Not specified | 6 |
5 | Ahn et al[40] | Quantitative | 63 | Korea | MERS Patients | Suicide, fatigue | Not specified | 6 |
6 | Lee et al[41] | Quantitative | 52 | Korea | MERS Patients | Depression, PTSD, fatigue | Not specified | 6 |
7 | Kim et al[42] | Quantitative | 112 | Korea | HCWs | PTSD, burnout | Not specified | 7 |
8 | Oh et al[43] | Quantitative | 313 | Korea | HCWs | Stress | Stress: 0.066 | 7 |
9 | Seo et al[44] | Quantitative | 171 | Korea | HCWs | Burnout | Not specified | 5 |
10 | Son et al[45] | Quantitative | 280 | Korea | HCWs and general public | PTSD | Not specified | 6 |
11 | Park et al[46] | Quantitative | 187 | Korea | HCWs | Stress | Not specified | 6 |
12 | Jeong et al[24] | Qualitative | 1692 | Korea | MERS patients and general public | Anxiety | Not specified | 7 |
13 | Al-Rabiaah et al[47] | Quantitative | 174 | Saudi Arabia | General public | Anxiety | Not specified | 7 |
14 | Park et al[48] | Quantitative | 63 | Korea | MERS Patients | PTSD, depression | Not specified | 7 |
15 | Cho et al[49] | Quantitative | 111 | Korea | General public | PTSD | PTSD: 0.3 | 7 |
16 | Kim et al[50] | Quantitative | 27 | Korea | General public | Depression | Not specified | 5 |
17 | Lee et al[51] | Quantitative | 359 | Korea | HCWs | PTSD | Not specified | 6 |
18 | Kim and Choi[52] | Quantitative | 215 | Korea | HCWs | Burnout, stress | Not specified | 6 |
19 | Bukhari et al[53] | Quantitative | 386 | Saudi Arabia | HCWs | Worry | Not specified | 6 |
20 | Mollers et al[54] | Quantitative | 72 | Netherlands | General public | PTSD | Not specified | 5 |
21 | Kim and Choi[52] | Quantitative | 215 | Korea | HCWs | PTSD: 0.017 | PTSD: 0.017 | 6 |
Table 2 39 studies that are included in meta-analysis for severe acute respiratory syndrome
Study ID | Ref. | Study type | Sample size | Country/region | Exposure | P value | Quality assessment (NOS) |
1 | Kwek et al[20] | Cross-sectional | 360 | Singapore | SARS patients | PTSD: 0.79; Depression: 0.7; Anxiety: 0.51 | 7 |
2 | Fang et al[55] | Cross-sectional | 1278 | China | SARS patients | Anxiety: 0.291; Depression: 0.705; PTSD: 0.2 | 8 |
3 | Liang[56] | Prospective cohort | 769 | China, Taiwan | SARS patients | PTSD: > 0.05; Anxiety: > 0.05 | 7 |
4 | Dang et al[57] | Cross-sectional | 549 | China | General public | Anxiety: < 0.00001; Depression: 0.000361 | 7 |
5 | Yip[58] | Prospective cohort | 218 | China, Hong Kong | SARS patients | Not specified | 6 |
6 | Cheng et al[59] | Cross-sectional | 10 | China, Hong Kong | SARS patients | Anxiety: > 0.05; Depression: > 0.05 | 5 |
7 | Wu et al[60] | Cross-sectional | 286 | China, Hong Kong | SARS patients | PTSD: < 0.001; Depression: < 0.05; Anxiety: < 0.01 | 6 |
8 | MaK et al[61] | Retrospective cohort | 126 | China, Hong Kong | SARS patients | Not specified | 5 |
9 | Lee et al[62] | Cross-sectional | 10511 | China, Hong Kong | Were not HCWs | Not specified | 7 |
10 | Hong et al[63] | Cross-sectional | 1050 | China | SARS patients | PTSD: 0.0323 | 7 |
11 | Wang[64] | Prospective cohort | 22 | China | SARS patients | Not specified | 4 |
12 | Hu et al[65] | Cross-sectional | 763 | China | Attended hospital for other reasons | Not specified | 5 |
13 | Chen et al[66] | Prospective cohort | 325 | China, Taiwan | Non-infected HCWs in the largest obligatory SARS hospital, with high SARS contact | Anxiety: 0.55 Depression: 0.93 | 6 |
14 | Ko et al[67] | Cross-sectional | 72 | China, Taiwan | General public of outbreak area | Depression: 0.02 | 5 |
15 | Lee et al[21] | Cross-sectional | 114 | China, Hong Kong | General public of outbreak area | Not specified | 6 |
16 | Hawryluck et al[68] | Cross-sectional | 652 | Canada, Toronto | General public of outbreak area | Depression: 0.85; PTSD: 0.82 | 7 |
17 | Liu et al[69] | Cross-sectional | 96 | China, Beijing | Non-infected HCWs of SARS hospital | Depression: < 0.05 | 7 |
18 | Su et al[70] | Prospective cohort | 57 | China, Taiwan | Non-infected HCWs in SARS outbreak region with high exposure risk vs low exposure risk | PTSD: > 0.05; Depression: < 0.05 | 7 |
19 | Lam et al[71] | Retrospective cohort | 116 | China, Hong Kong | SARS patients | Not specified | 6 |
20 | Shi et al[72] | Prospective cohort | 87 | China, Beijing | SARS outbreak region | Not specified | 5 |
21 | Huang et al[73] | Cross-sectional | 4481 | China, Beijing | Were not HCWs | Not specified | 6 |
22 | Yu et al[74] | Prospective cohort | 180 | China, Hong Kong | General public of outbreak area | Not specified | 5 |
23 | Chang and Sivam[75] | Cross-sectional | 146 | Singapore | General public of outbreak area | Not specified | 5 |
24 | Moldofsky and Patcai[76] | Retrospective cohort | 107 | Canada, Toronto | SARS patients, who were HCWs | Not specified | 6 |
25 | Sun et al[77] | Prospective cohort | 1557 | China, Xianxi | SARS patients | PTSD: 0.67 | 7 |
26 | Lau et al[78] | Cross-sectional | 333 | China, Hong Kong | General public of outbreak area | Not specified | 5 |
27 | Reynolds et al[79] | Cross-sectional | 89 | Canada | General public of outbreak area, quarantined; non-infected HCWs in SARS outbreak region, quarantined | Not specified | 5 |
28 | Lancee et al[80] | Cross-sectional | 613 | Canada, Toronto | Non-infected HCWs in SARS outbreak region | Not specified | 6 |
29 | Lin et al[81] | Cross-sectional | 6280 | China, Taiwan, Taichung | Non-infected HCWs in in region without major SARS outbreak | Not specified | 6 |
30 | Gao et al[82] | Prospective cohort | 127 | China, Tianjin | SARS patients | Not specified | 5 |
31 | Xu et al[83] | Cross-sectional | 129 | China, Xianxi | Non-infected HCWs in SARS hospital | PTSD: > 0.05 | 6 |
32 | Wong et al[84] | Cross-sectional | 0 (?) | China, Hong Kong | Non-infected HCWs from SARS hospitals | Not specified | 4 |
33 | Sim et al[85] | Cross-sectional | 90 | Singapore | Non-infected HCWs in SARS outbreak region | Not specified | 5 |
34 | Wu et al[19] | Cross-sectional | 133 | China, Beijing | Non-infected HCWs in SARS hospital | Not specified | 6 |
35 | Chen et al[86] | Cross-sectional | 103 | China, Taiwan, Kaohsiung | Non-infected HCWs in SARS hospital, with high SARS contact; non-infected HCWs in SARS hospital; with low SARS contact | Not specified | 6 |
36 | Tham et al[87] | Cross-sectional | 90 | Singapore | Non-infected HCWs in SARS hospital with extra risk of exposure | Not specified | 5 |
37 | Maunder et al[88] | Cross-sectional | 90 | Canada, Toronto | Non-infected HCWs of outbreak area, unspecified (mix of SARS affected and non SARS affected hospitals | PTSD: < 0.01 | 7 |
38 | Mak et al[89] | Retrospective cohort | 126 | China, Hong Kong | SARS patient | Not specified | 6 |
39 | McAlonan et al[90] | Cross-sectional | 0 (?) | China, Hong Kong | Non-infected HCWs in SARS outbreak region with high exposure risk vs low exposure risk | Not specified | 3 |
Table 3 Pooled prevalence and confidence interval of anxiety across Middle East respiratory syndrome coronavirus, severe acute respiratory syndrome coronavirus and severe acute respiratory syndrome coronavirus-2
Anxiety | Prevalence (%) | 95%CI | Heterogeneity I2 (%) |
MERS | 17.35 | 8.36-36.02 | 95.62 |
SARS-CoV-2 | 21.48 | 18.68-24.71 | 99.76 |
SARS-CoV | 25.20 | 18.41-34.5 | 93.47 |
Table 4 Pooled prevalence and confidence interval of depression across three diseases
Depression | Prevalence (%) | 95%CI | Heterogeneity I2 (%) |
MERS | 33.65 | 22.02-51.42 | 69.86 |
SARS-CoV-2 | 27.64 | 24.59-31.06 | 99.69 |
SARS-CoV | 23.10 | 18.14-29.4 | 95.03 |
Table 5 Pooled prevalence and confidence interval of post-traumatic stress disorder across three diseases
PTSD | Prevalence (%) | 95%CI | Heterogeneity I2 (%) |
MERS | 35.97 | 29.6-43.72 | 75.2 |
SARS-CoV-2 | 25.03 | 18.15-34.51 | 99.58 |
SARS-CoV | 18.20 | 14.94-22.18 | 91.37 |
Table 6 Subgroup analysis on Middle East respiratory syndrome data based on different age groups
Subgroup-age | MERS | |||
Prevalence (%) | 95%CI | Heterogeneity I2 (%) | ||
Anxiety | 10-19 | - | - | - |
20-29 | - | - | - | |
30-39 | - | - | - | |
40-49 | 18.51 | 8.11-42.23 | 96.43 | |
50-59 | - | - | - | |
Depression | 20-29 | - | - | - |
30-39 | - | - | - | |
40-49 | 38.45 | 25.81-57.26 | 60.55 | |
50-59 | - | - | - | |
PTSD | 20-29 | 49.70 | 38.2-64.67 | 0 |
30-39 | 19.32 | 14.82-25.18 | 0 | |
40-49 | 26.69 | 13.21-53.91 | 80.63 | |
50-59 | - | - | - | |
60-69 | 17.87 | 12.4-25.74 | 0 |
Table 7 Subgroup analysis on severe acute respiratory syndrome coronavirus-2 data based on different age groups
Subgroup-age | SARS-CoV-2 | |||
Prevalence (%) | 95%CI | Heterogeneity I2 (%) | ||
Anxiety | 10-19 | 34.40 | 33.17-35.68 | 0 |
20-29 | 25.70 | 19.38-34.08 | 99.25 | |
30-39 | 22.86 | 17.86-29.26 | 99.64 | |
40-49 | 15.59 | 9.65-25.17 | 99.66 | |
50-59 | 20.13 | 10.43-38.84 | 99.42 | |
60-69 | 7.75 | 0.79-76.29 | 99.47 | |
Depression | 10-19 | 43.91 | 42.12-45.77 | 0 |
20-29 | 31.03 | 24.04-40.04 | 99.12 | |
30-39 | 30.4 | 25.15-36.74 | 99.48 | |
40-49 | 20.0 | 13.26-30.18 | 99.4 | |
50-59 | 19.98 | 15.84-25.19 | 92.68 | |
60-69 | 4.93 | 3.45-7.05 | 90.00 | |
PTSD | 20-29 | 32.40 | 6.54-160.49 | 98.29 |
30-39 | 21.96 | 12.77-37.78 | 99.33 | |
40-49 | 27.72 | 19.88-38.66 | 97.59 | |
50-59 | 5.38 | 3.76-7.69 | 0 | |
60-69 | - | - | - |
Table 8 Subgroup analysis on severe acute respiratory syndrome coronavirus data based on different age groups
Subgroup-age | SARS-CoV | |||
Prevalence (%) | 95%CI | Heterogeneity I2 (%) | ||
Anxiety | 10-19 | - | - | - |
20-29 | - | - | - | |
30-39 | 24.60 | 13.29-45.55 | 85.81 | |
40-49 | 15.63 | 10.97-22.26 | 60.57 | |
50-59 | 51.62 | 38.53-69.16 | 0 | |
Depression | 20-29 | - | - | - |
30-39 | 27.47 | 16.09-46.9 | 89.58 | |
40-49 | 20.30 | 13.36-30.85 | 81.57 | |
50-59 | 22.49 | 14.8-34.17 | 0 | |
60-69 | 25.85 | 17.69-37.75 | 0 | |
PTSD | 20-29 | 24.43 | 15.53-38.44 | 72.18 |
30-39 | 32.13 | 23.1-44.68 | 89.33 | |
40-49 | 11.68 | 8.45-16.15 | 86.20 | |
50-59 | 67.80 | 43.57-100 | 0 | |
60-69 | 7.54 | 2.64-21.54 | 53.28 |
Table 9 Subgroup analysis on Middle East respiratory syndrome data based on different type of people
Subgroup-occupation | MERS | |||
Prevalence (%) | 95%CI | Heterogeneity I2 (%) | ||
Anxiety | General Public | 6.04 | 2.86-12.79 | 93.9 |
HCW | - | - | - | |
Patient | 33.95 | 20.65-55.82 | 68.57 | |
Depression | General Public | 40.70 | 18.89-87.71 | 0 |
HCW | 20.52 | 11.81-35.67 | 41.71 | |
Patient | 41.69 | 23.73-73.22 | 71.77 | |
PTSD | General Public | 19.02 | 14.01-25.81 | 0 |
HCW | 49.87 | 45.09-55.16 | 0 | |
Patient | 37.70 | 27.47-51.74 | 0 |
Table 10 Subgroup analysis on severe acute respiratory syndrome coronavirus-2 data based on different type of people
Subgroup-occupation | SARS-CoV-2 | |||
Prevalence (%) | 95%CI | Heterogeneity I2 (%) | ||
Anxiety | General Public | 21.18 | 17.88-25.09 | 99.82 |
HCW | 22.35 | 17.42-28.66 | 99.36 | |
Patient | - | - | - | |
Depression | General Public | 27.6 | 23.36-32.24 | 99.8 |
HCW | 27.71 | 23.22-33.08 | 98.79 | |
Patient | - | - | - | |
PTSD | General Public | 24.83 | 14.97-41.18 | 99.67 |
HCW | 25.16 | 16.62-38.08 | 99.33 | |
Patient | - | - | - |
Table 11 Subgroup analysis on studies under severe acute respiratory syndrome coronavirus data based on different type of people
Subgroup-occupation | SARS-CoV | |||
Prevalence (%) | 95%CI | Heterogeneity I2 (%) | ||
Anxiety | General Public | 26.19 | 11.93-57.48 | 98.22 |
HCW | 98.44 | 22.67-427.49 | 0 | |
Patient | 24.21 | 17.34-33.79 | 85.16 | |
Depression | General Public | 23.31 | 14.64-37.11 | 97.97 |
HCW | 25.42 | 13.74-47.03 | 90.29 | |
Patient | 21.96 | 16.86-28.6 | 78.1 | |
PTSD | General Public | 18.36 | 13.59-24.81 | 81.69 |
HCW | 16.97 | 12.28-23.45 | 91.8 | |
Patient | 19.80 | 14.28-27.46 | 90.44 |
Table 12 Sensitivity analysis for anxiety and depression studies under severe acute respiratory syndrome coronavirus-2
Exposure | Outcome | Prevalence with 95%CI (before) | Prevalence with 95%CI (after) | P value | |
(g) | SARS-CoV-2 | Anxiety | 21.48 (18.66-24.71) | 25.82 (23.98-27.8) | < 0.05 |
(h) | SARS-CoV-2 | Depression | 27.64 (24.59-31.06) | 29.3 (26.98-31.81) | > 0.05 |
- Citation: Delanerolle G, Zeng Y, Shi JQ, Yeng X, Goodison W, Shetty A, Shetty S, Haque N, Elliot K, Ranaweera S, Ramakrishnan R, Raymont V, Rathod S, Phiri P. Mental health impact of the Middle East respiratory syndrome, SARS, and COVID-19: A comparative systematic review and meta-analysis. World J Psychiatry 2022; 12(5): 739-765
- URL: https://www.wjgnet.com/2220-3206/full/v12/i5/739.htm
- DOI: https://dx.doi.org/10.5498/wjp.v12.i5.739